Ridaura Related Published Studies
Well-designed clinical trials related to Ridaura (Auranofin)
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. [1999.05]
A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]
CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA. [1998]
Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. [1997.08]
Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial. [1996.11]
A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. [1996.08]
Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study. [1995.07]
Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma. [1994.07]
Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin. [1994.03]
Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. [1993.10]
Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis. The European Multicentre Study Group. [1993.05]
The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. [1993.05]
Auranofin in the treatment of steroid dependent asthma: a double blind study. [1992.05]
Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. [1992.04]
Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. [1992.03]
Prevention of appearance of radiological lesions in early rheumatoid arthritis: a randomized, single-blind study comparing intra-articular rifamycin with auranofin. [1992.02]
Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. [1991.08]
A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. [1991.08]
A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritis. [1990.12]
A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. [1990.08]
Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. [1990.04]
[The treatment of ankylosing spondylitis with auranofin (Ridaura)] [1990.03]
Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. [1990.03]
Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments. [1989]
Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. [1988.12]
A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis. [1988.07]
Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study. [1988.02.15]
Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. [1988.01]
The cost effectiveness of auranofin: results of a randomized clinical trial. [1988.01]
Well-designed clinical trials possibly related to Ridaura (Auranofin)
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. [2000.06]
Interventions for psoriatic arthritis. [2000]
Multiple-outcome meta-analysis of clinical trials. [1996.03.15]
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. [1995.12]
Analysis of repeated categorical data using generalized estimating equations. [1994.06.15]
Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. [1993.10]
[Circulating immune complexes and complement fragment iC3b in chronic polyarthritis during 12 months therapy with oral enzymes in comparison with oral gold] [1992]
IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. [1991.09]
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. [1990.04]
Other research related to Ridaura (Auranofin)
Erythrocyte Membrane Gold Levels After Treatment with Auranofin and Sodium Aurothiomalate. [2008.07.24]
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. [2008.03.19]
Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. [2006.12.01]
Other possibly related research studies
Analysis of the expression of heme oxygenase-1 gene in human alveolar epithelial cells exposed to cigarette smoke condensate. [2006.05]
Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. [2007.12.15]
Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. [2007.06]
Clinical pharmacology of gold. [2008.06]
|
